Virtus Biotech Clinical Trials ETF
18 hedge funds and large institutions have $39.5M invested in Virtus Biotech Clinical Trials ETF in 2018 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 1 closing their positions.
600% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 1
331% more capital invested
Capital invested by funds: $9.17M → $39.5M (+$30.4M)
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
50% more funds holding
Funds holding: 12 → 18 (+6)
21.28% more ownership
Funds ownership: 29.29% → 50.58% (+21%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Niemann Capital Management
Stateline,
Nevada
|
+$16.6M |
| 2 |
UCFA
United Capital Financial Advisors
Irving,
Texas
|
+$7.43M |
| 3 |
Envestnet Asset Management
Chicago,
Illinois
|
+$2.05M |
| 4 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
+$699K |
| 5 |
Stifel Financial
St. Louis,
Missouri
|
+$378K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$452K |
| 2 |
CA
Calton & Associates
Tampa,
Florida
|
-$74K |
| 3 |
Goldman Sachs
New York
|
-$61.6K |
| 4 |
ASN
Advisory Services Network
Atlanta,
Georgia
|
-$14.3K |
BBC Hedge Fund Activity: Q1 2018 in Review
18 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech Clinical Trials ETF (BBC) for Q1 2018, worth a combined $39.5M — up 331% from $9.17M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new BBC positions and 1 closed out — a net gain of 6 holders — while 6 added to existing stakes and 3 trimmed.
The largest buyer was Niemann Capital Management, opening a new position worth an estimated $16.6M. The largest seller was Jane Street, cutting an estimated $452K.
- 18 institutional investors held Virtus Biotech Clinical Trials ETF (BBC) as of Q1 2018, up from 12 in Q4 2017.
- Funds reported $39.5M of Virtus Biotech Clinical Trials ETF stock for Q1 2018, up 331% quarter-over-quarter.
- 7 funds opened new Virtus Biotech Clinical Trials ETF positions in Q1 2018 and 1 closed out, a net change of +6 holders.
- The largest Virtus Biotech Clinical Trials ETF buyer in Q1 2018 was Niemann Capital Management, an estimated $16.6M added.
- The largest Virtus Biotech Clinical Trials ETF seller in Q1 2018 was Jane Street, an estimated $452K sold.
Based on aggregated 13F filings for Q1 2018.